Drug Profile
Tamsulosin controlled-release - GL PharmTech
Alternative Names: GL2702; GL2702 GLARS-NF1; GLC2TA; Incrementally modified tamsulosin; Tamsulosin GLARS; Tamsulosin new QD; Tamsulosin ODLatest Information Update: 11 Dec 2021
Price :
$50
*
At a glance
- Originator GL PharmTech
- Class Amines; Phenyl ethers; Small molecules; Sulfonamides
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 26 Sep 2019 Discontinued - Phase-III for Benign prostatic hyperplasia in South Korea (PO)
- 01 Oct 2015 GL PharmTech completes a phase III trial in Benign prostatic hyperplasia in South Korea (NCT02303769) (PO, 0.4mg)
- 06 May 2015 Controlled-release tamsulosin is still in phase III trials for Benign prostatic hyperplasia in South Korea (PO, 0.4mg)